Jun 14, 2023 / 11:40PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Great. Good afternoon, everyone. Thanks so much for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. Really pleased to have the team from Moderna here today. So we have Jamie Mock, CFO; and Lavina Talukdar, Head of IR.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPSo with that, maybe we'll start here with some financial questions. You provided some guidance in the beginning of the year and -- on COGS and other aspects. Could you just help us understand what COGS is going to look like for this year and beyond? And what the key components are on this line and how they change over time as commercialize COVID, as that market is better understood and then additional assets are commercialized?
James M. Mock - Moderna, Inc. - CFO
Terrific. Yes. Well, first, thanks for having us, Salveen. Pleasure to be here. And thanks, everybody, for joining. Yes. So as we transition
Trustpilot
